-
Dr. He on the Potential of Immune Checkpoint Inhibitors in GI Cancers
Aiwu Ruth He, MD, PhD, summarizes current treatment approaches in gastrointestinal (GI) cancers.
Category: News
-
Dr. Pishvaian on Precision Medicine in GI Cancer
Michael Pishvaian, MD, PhD, discusses the use of precision medicine, specifically molecular profiling in patients with gastrointestinal (GI) cancers.
Category: News
-
Dr. Pishvaian on Molecular Alteration in Pancreatic Cancer
Michael Pishvaian, MD, PhD, discusses the background of a study investigating molecular alterations for patients with pancreatic cancer.
Category: News
-
Dr. Marshall on the Importance of Testing for BRAF Mutations in mCRC
John L. Marshall, MD, discusses the specificity now required in the treatment of patients with metastatic colorectal cancer (mCRC).
Category: News
-
Sequencing Strategies in Pancreatic Cancer
Fadi Braiteh, MD, and John L. Marshall, MD, provide insight regarding dosing and administration strategies with nab-paclitaxel/gemcitabine therapy in pancreatic cancer.
Category: News
-
Entrectinib Effective in Pancreatic Cancer Subgroup
In an interview with OncLive , Michael Pishvaian, MD, PhD, discusses the findings with entrectinib in this population, as well as the potential implications of widespread molecular testing in pancreatic cancer.
Category: News
-
Marshall Recaps Milestones in CRC Paradigm
John L. Marshall, MD, recaps some of the biggest CRC advancements of 2017, and explains what those successes mean for the treatment paradigm moving forward.
Category: News
-
New GI Cancer Studies: Curious Failures, Hidden Gems
Dr. John Marshall on recent publications, both positive and negative, that may change your practice.
Category: News
-
Dr. Marshall Discusses Frontline Treatment for CRC
John L. Marshall, MD, discusses frontline treatment options for patients with colorectal cancer (CRC).
Category: News
-
Deciding the Duration of Adjuvant Chemotherapy in a Patient With Stage III Colon Cancer: When Can Less Be More?
Patients with stage III colon cancer benefit from adjuvant chemotherapy with FOLFOX or CAPOX.
Category: News